Multi-array impedimetric biosensors for the detection of concussion and traumatic brain injuries

US12105087B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12105087-B2
Application numberUS-201716467116-A
CountryUS
Kind codeB2
Filing dateDec 11, 2017
Priority dateDec 9, 2016
Publication dateOct 1, 2024
Grant dateOct 1, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention includes an ex-situ biosensors that impedimetrically detect one or more target biomarkers of brain injury or disease in a bodily fluid sample derived from a patient. The biosensors include a multi-array of vertically aligned platinum wires having immobilized thereon antibody and/or aptamer that specifically and selectively bind to the one or more target biomarkers. An electrochemical impedance signal is generated, and a change in electrochemical impedance is indicative of the presence of the one or more target biomarker(s) in the bodily fluid sample. The biosensors are point-of-care, on-demand devices useful in a medical and domestic environment.

First claim

Opening claim text (preview).

The invention claimed is: 1. A portable, ex-situ system to impedimetrically detect one or more target biomarkers related to brain injury or disease in a bodily fluid sample of a patient, comprising: a conducting material interface, comprising: an epoxy resin; and a multi-array of vertically aligned conducting metal wires selected from the group consisting of platinum wires, gold wires, iridium wires, ruthenium wires, palladium wires, osmium wires, and alloys and combinations thereof, each of the plurality of conducting metal wires having a first end and an opposite second end with the first end cast in the epoxy resin; a thiol-based compound applied to the second end of the plurality of conducting wires to form a thiol treated surface; an immobilization agent applied to the thiol treated surface; and at least one biotinylated antibody and/or aptamer applied to the immobilization agent, selected to bind with the immobilization agent and the one or more target biomarkers related to brain injury or disease; a signaling agent comprising an electrochemical impedance signal generated by binding of the at least one biotinylated antibody and/or aptamer with the one or more target biomarkers related to brain injury or disease; and the bodily fluid sample derived from the patient and in contact with the at least one biotinylated antibody and/or aptamer to detect the one or more target biomarkers related to brain injury or disease, wherein the system is structured such that in its use a change in electrochemical impedance indicates a presence of the one or more target biomarkers related to brain injury or disease in the bodily fluid sample and binding of the at least one biotinylated antibody and/or aptamer with the one or more target biomarkers in the bodily fluid sample, and wherein the system is structured such that in its use an absence of a change in electrochemical impedance indicates an absence of the one or more target biomarkers related to brain injury or disease in the bodily fluid sample. 2. The system of claim 1 , wherein the bodily fluid sample is a blood sample. 3. The system of claim 1 , wherein the one or more target biomarkers related to brain injury or disease are selected from the group consisting of Tau proteins, Glial Fibrilar Acidic Protein (GFAP) and Ubiquitin C-Terminal Hydrolase L1 (UCH-L1). 4. The system of claim 1 , wherein the immobilization agent is selected from the group consisting of avidin, streptavidin, neutravidin and mixtures thereof. 5. The system of claim 1 , wherein the antibody and/or aptamer sensor is effective to impedimetrically detect simultaneously a plurality of target biomarkers related to brain injury or disease in the bodily fluid sample. 6. The system of claim 1 , wherein the multi-array of vertically aligned conducting material wires are arranged in a concentric configuration.

Assignees

Inventors

Classifications

  • Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event · CPC title

  • Electrodes · CPC title

  • Investigating or analysing materials by the use of electric, electrochemical, or magnetic means (G01N3/00 – G01N25/00 take precedence; measurement or testing of electric or magnetic variables or of electric or magnetic properties of materials G01R) · CPC title

  • related to diseases not provided for elsewhere · CPC title

  • C07K16/18Primary

    against material from animals or humans · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12105087B2 cover?
The invention includes an ex-situ biosensors that impedimetrically detect one or more target biomarkers of brain injury or disease in a bodily fluid sample derived from a patient. The biosensors include a multi-array of vertically aligned platinum wires having immobilized thereon antibody and/or aptamer that specifically and selectively bind to the one or more target biomarkers. An electrochemi…
Who is the assignee on this patent?
Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education, Univ Pittsburgh Commonwealth Sys Higher Education
What technology area does this patent fall under?
Primary CPC classification C07K16/18. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).